Senseonics partners with Sequel to use Eversense 365 CGM implant as AID

Image courtesty of Senseonics.

The FDA recently cleared Senseonic's Eversense 365 CGM as an integrated CGM (iCGM), opening the door for its use in automated insulin delivery (AID) systems—a major advancement for those using insulin pump therapy.

Unlike traditional CGMs, Eversense 365 lasts up to a full year and requires far fewer fingerprick calibrations. Clearance by the FDA paves the way for the device to now be used alongside insulin pumps, which could significantly streamline diabetes management.

“Sequel is committed to investing in innovations that empower people with diabetes with options in how they manage their diabetes,” said Sequel CEO and Co-Founder Alan Lotvin, M.D. “By partnering with Senseonics, a company pioneering long-duration CGM, we aim to deliver the flexibility people want to personalize their diabetes management on their terms.”

The first company to make this integration a reality is Sequel, working in collaboration with Senseonics, the maker of Eversense. Sequel’s insulin pump, called Twiist, developed with support from Deka Research & Development, received FDA clearance in March 2024. Twiist is powered by an app from Tidepool, a non-profit focused on open-source diabetes meddtech, and is set to launch commercially in the US during the second quarter of 2025.

Sequel also recently announced a partnership with Abbott, aiming to integrate Twiist with the Freestyle Libre 3 Plus sensor. While this development centers on Abbott's system, it signals strong momentum in expanding CGM-pump interoperability across the industry.

Financial analysts at BTIG are cautiously optimistic. They say the commercial impact for Senseonics may be modest in the early months of Twiist’s launch but view the partnership as a crucial first step in making Eversense more accessible beyond standalone use.

At a March TD Cowen event, Mukul Jain, Chief Operating Officer at Senseonics, confirmed that the company has already completed successful prototype integrations with other insulin pump makers. He noted that being compatible with multiple devices is essential since people often change their CGM or pump over time.

Jain emphasized that while insulin pump integration is a key milestone, many people still manage their diabetes with multiple daily injections (MDI)—and Senseonics is committed to serving both groups effectively.

For insulin pump users eager for longer-lasting, low-maintenance CGMs, this is a major step forward. Eversense 365’s move into the AID space may soon expand choices - leading to better control for managing diabetes!

For more information, visit  www.sequelmedtech.com and www.eversensediabetes.com.